Table 1 Descriptive characteristics of the entire cohort and stratified by hormonal status
Characteristics | All patients | ER+ or PR+ | ER− and PR− |
|---|---|---|---|
n (%) | n (%) | n (%) | |
Totala | 1,202 | 767 | 387 |
Age | |||
 <50 years | 452 (37.6) | 281 (36.6) | 150 (38.8) |
 50–64 years | 546 (45.4) | 357 (46.5) | 170 (43.9) |
 ≥65 years | 204 (17.0) | 129 (16.8) | 67 (17.3) |
Menopausal statusa | |||
 Pre-menopausal | 486 (40.7) | 316 (41.5) | 146 (37.8) |
 Post-menopausal | 709 (59.3) | 446 (58.5) | 240 (62.2) |
Race | |||
 White | 961 (80.0) | 629 (82.0) | 297 (76.7) |
 Black | 153 (12.7) | 88 (11.5) | 58 (15.0) |
 Other | 88 (7.3) | 50 (6.5) | 32 (8.3) |
Baseline body surface area | |||
 ≤2 m2 | 930 (77.4) | 595 (77.6) | 298 (77.0) |
 >2 m2 | 272 (22.6) | 172 (22.4) | 89 (23.0) |
Body mass indexa | |||
 <30 kg/m2 | 769 (64.1) | 499 (65.3) | 238 (61.5) |
 30 to <35 kg/m2 | 226 (18.8) | 136 (17.8) | 81 (20.9) |
 ≥35 kg/m2 | 204 (17.0) | 129 (16.9) | 68 (17.6) |
ECOG performance status | |||
 0 | 937 (78.0) | 608 (79.3) | 295 (76.2) |
 1 | 241 (20.0) | 145 (18.9) | 84 (21.7) |
 2–4 | 24 (2.0) | 14 (1.8) | 8 (2.1) |
Stagea | |||
 I | 288 (24.1) | 188 (24.6) | 96 (25.0) |
 II | 678 (56.7) | 437 (57.1) | 218 (56.8) |
 III | 230 (19.2) | 140 (18.3) | 70 (18.2) |
Medical history | |||
 Prior chemotherapy | 98 (8.2) | 49 (6.4) | 46 (11.9) |
 Recent surgery | 565 (47.0) | 354 (46.2) | 188 (48.6) |
 Diabetes | 96 (8.0) | 55 (7.2) | 36 (9.3) |
 CHF or MI | 24 (2.0) | 16 (2.1) | 5 (1.3) |
 Lung disease | 30 (2.5) | 18 (2.3) | 11 (2.8) |
 History of anemia | 85 (7.1) | 57 (7.4) | 23 (5.9) |
Number of comorbidities | |||
 0 | 1,027 (85.4) | 659 (85.9) | 329 (85.0) |
 1 | 153 (12.7) | 97 (12.6) | 49 (12.7) |
 ≥2 | 22 (1.8) | 11 (1.4) | 9 (2.3) |
Chemotherapy treatment | |||
 Standard AC or EC | 527 (43.8) | 334 (43.5) | 170 (43.9) |
 Dose dense AC or EC | 137 (11.4) | 82 (10.7) | 51 (13.2) |
 CMF | 123 (10.2) | 90 (11.7) | 31 (8.0) |
 CAF or CEF | 155 (12.9) | 105 (13.7) | 47 (12.1) |
 TAC or TEC | 83 (6.9) | 54 (7.0) | 27 (7.0) |
 Paclitaxel/docetaxel | 68 (5.7) | 41 (5.3) | 25 (6.5) |
 AT or ET | 42 (3.5) | 22 (2.9) | 16 (4.1) |
 Other | 67 (5.6) | 39 (5.1) | 20 (5.2) |